Spots Global Cancer Trial Database for An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread
Official Title: A Phase 1/2 Study of Relatlimab (Anti-LAG-3 Monoclonal Antibody) Administered in Combination With Both Nivolumab (Anti-PD-1 Monoclonal Antibody) and BMS-986205 (IDO1 Inhibitor) or in Combination With Both Nivolumab and Ipilimumab (Anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors
Study ID: NCT03459222
Conditions
Study Description
Brief Summary: The purpose of this study is to demonstrate the safety and preliminary activity with triple combinations of relatlimab in combination with nivolumab and BMS-986205, or in combination with nivolumab and ipilimumab in immunotherapy-naive and pretreated populations across select advanced tumor types.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Local Institution - 0006, Duarte, California, United States
Local Institution - 0003, Aurora, Colorado, United States
Local Institution - 0004, Baltimore, Maryland, United States
Local Institution - 0005, Saint Louis, Missouri, United States
Local Institution, Cleveland, Ohio, United States
Local Institution - 0001, Germantown, Tennessee, United States
Local Institution - 0012, Wollstonecraft, New South Wales, Australia
Local Institution - 0011, Nedlands, Western Australia, Australia
Hopital De La Timone, Marseille Cedex 5, , France
Institut Claudius Regaud, Toulouse Cedex 9, , France
Institute Gustave Roussy, Villejuif, , France
Local Institution - 0010, Forlì, , Italy
Local Institution - 0009, Napoli, , Italy
Local Institution - 0023, Rome, , Italy
Local Institution - 0019, Barcelona, , Spain
Local Institution - 0021, Madrid, , Spain
Local Institution - 0018, Madrid, , Spain
Local Institution - 0022, Málaga, , Spain
Local Institution - 0020, Pamplona, , Spain
Local Institution - 0008, Lausanne, , Switzerland
Local Institution - 0007, Zuerich, , Switzerland
Local Institution - 0013, Headington, , United Kingdom
Local Institution - 0014, Newcastle Upon Tyne, , United Kingdom
Contact Details
Name: Bristol-Myers Squibb
Affiliation: Bristol-Myers Squibb
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
